Prophylaxis against covid-19: living systematic review and network meta-analysis

Jessica J Bartoszko,1,7 Reed A C Siemieniuk,2 Elena Kum,1,7 Anila Qasim,1,7 Dena Zeraatkar,1,7 Long Ge,2,7 Mi Ah Han,3 Behnam Sadeghirad,1,4 Arnaw Agawan,1,5 Thomas Agoritsas,1,6
Derek K Chu,1,7 Rachel Couban,4 Andrea J Darzi,1 Tahira Devji,1 Maryam Ghadimi,1 Kimia Honarmand,8 Ariel Izcovich,9 Assem Khamis,10 Francois Lamontagne,11 Mark Loeb,1,7
Maura Marcucci,1,7 Shelley L McLeod,1,2,3 Sharhzad Motaghi,1 Srinivas Murthy,14
Reem A Mustafa,1,7 John D Neary,7 Hector Pardo-Hernandez,16,17 Gabriel Rada,1,8,9
Bram Rochwerg,17 Charlotte Switzer,1 Britta Tendal,20 Lehana Thabane,1 Per O Vandvik,21
Robin W M Vernooij,2,22,23 Andrés Viteri-García,18,24 Ying Wang,1 Liang Yao,1 Zhikang Ye,1
Gordon H Guyatt,1,7 Romina Brignardello-Petersen1

ABSTRACT

OBJECTIVE
To determine and compare the effects of drug prophylaxis on SARS-CoV-2 infection and covid-19.

DESIGN
Living systematic review and network meta-analysis.

DATA SOURCES
World Health Organization covid-19 database, a comprehensive multilingual source of global covid-19 literature to 25 March 2021, and six additional Chinese databases to 20 February 2021.

STUDY SELECTION
Randomised trials of people at risk of covid-19 who were assigned to receive prophylaxis or no prophylaxis (standard care or placebo). Pairs of reviewers independently screened potentially eligible articles.

METHODS
Random effects bayesian network meta-analysis was performed after duplicate data abstraction. Included studies were assessed for risk of bias using a modification of the Cochrane risk of bias 2.0 tool, and certainty of evidence was assessed using the grading of recommendations assessment, development, and evaluation (GRADE) approach.

RESULTS
The first iteration of this living network meta-analysis includes nine randomised trials—six of hydroxychloroquine (n=6059 participants), one of ivermectin combined with iota-carrageenan (n=234), and two of ivermectin alone (n=540), all compared with standard care or placebo. Two trials (one of ramipril and one of bromhexine hydrochloride) did not meet the sample size requirements for network meta-analysis. Hydroxychloroquine has trivial to no effect on admission to hospital (risk difference 1 fewer per 1000 participants, 95% credible interval 3 fewer to 4 more; high certainty evidence) or mortality (1 fewer per 1000, 2 fewer to 3 more; high certainty).

Hydroxychloroquine probably does not reduce the risk of laboratory confirmed SARS-CoV-2 infection (2 more per 1000, 18 fewer to 28 more; moderate certainty), of hospital admission and mortality, probably increases adverse effects leading to drug discontinuation (19 more per 1000, 1 fewer to 70 more; moderate certainty), and may have trivial to no effect on suspected, probable, or laboratory confirmed SARS-CoV-2 infection (15 fewer per 1000, 95% credible interval 3 fewer to 4 more; high certainty evidence) or mortality (1 fewer per 1000, 2 fewer to 3 more; high certainty).

Hydroxychloroquine probably does not reduce the risk of laboratory confirmed SARS-CoV-2 infection (2 more per 1000, 18 fewer to 28 more; moderate certainty), of hospital admission and mortality, probably increases adverse effects leading to drug discontinuation (19 more per 1000, 1 fewer to 70 more; moderate certainty), and may have trivial to no effect on suspected, probable, or laboratory confirmed SARS-CoV-2 infection (15 fewer per 1000, 95% credible interval 3 fewer to 4 more; high certainty evidence) or mortality (1 fewer per 1000, 2 fewer to 3 more; high certainty).

CONCLUSIONS
Hydroxychloroquine prophylaxis has trivial to no effect on hospital admission and mortality, probably increases adverse effects, and probably does not reduce the risk of SARS-CoV-2 infection. Because of serious risk of bias and very serious imprecision, and thus very low certainty of evidence, the effects of ivermectin combined with iota-carrageenan on laboratory confirmed covid-19 (52 fewer per 1000, 58 fewer to 37 fewer), ivermectin alone on laboratory confirmed infection (50 fewer per 1000, 59 fewer to 16 fewer) and suspected, probable, or laboratory confirmed infection (159 fewer per 1000, 165 fewer to 144 fewer) remain very uncertain.

WHAT IS ALREADY KNOWN ON THIS TOPIC

Prophylaxis is effective and commonly used for viruses, including HIV and hepatitis B

Several interventions are being assessed as potential prophylaxis agents for covid-19, including repurposed drugs and antiviral based antibodies

If effective against covid-19, prophylaxis could also have a major impact worldwide to prevent infection and attenuate disease, especially in those at high risk of death

WHAT THIS STUDY ADDS

Hydroxychloroquine did not reduce the rate of SARS-CoV-2 infection, admission to hospital, or mortality

More people discontinued hydroxychloroquine because of adverse events

As studies on ivermectin so far have been small it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection

RESEARCHERS’ NOTE

This article is a living systematic review that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication.

BMJ first published as 10.1136/bmj.n949 on 26 April 2021. Downloaded from http://www.bmj.com on 1 August 2022 by guest. Protected by copyright.
Introduction
As of 30 March 2021, more than 127 million people have been infected with SARS-CoV-2, the virus responsible for covid-19; of these, more than 2.7 million have died. Cases and deaths continue to rise as SARS-CoV-2 variants of concern become increasingly widespread. Because of vaccine hesitancy, contraindications to receiving the vaccine, and potential reduced vaccine effectiveness against these variants of concern, drug and antibody prophylaxis, if effective, will be an important intervention against covid-19. Drugs used as pre-exposure prophylaxis in a high risk population and post-exposure prophylaxis are effective and commonly used for other viruses, including HIV and hepatitis B. If effective against covid-19, these drugs could also have a monumental impact worldwide to prevent SARS-CoV-2 infection and attenuate disease, especially in those at high risk of death. Researchers around the world are therefore enrolling participants in randomised trials of drugs and antiviral antibodies for prophylaxis against covid-19.

Clinicians, patients, guideline bodies, and government agencies face challenges in interpreting the results from trials that are being published at a rate never encountered previously. This environment necessitates well developed summaries that can distinguish between trustworthy and untrustworthy evidence.

Living systematic reviews and network meta-analyses resolve an important limitation of traditional systematic reviews, which provide an overview of the relevant evidence only at a specific time. The ability of a living network meta-analysis to present a complete, broad, and up-to-date view of the evidence makes it ideal to inform the development of practice recommendations, ideally in the form of living clinical practice guidelines. Network meta-analysis, rather than pairwise meta-analysis, provides useful information about the comparative effectiveness of interventions that have not been tested head to head. The lack of such direct comparisons is certain to limit inferences in the covid-19 setting; therefore, network meta-analysis is critical to inform the selection of the best drug among all alternative options. Moreover, the incorporation of indirect evidence can strengthen evidence from comparisons that were tested head to head.

In this living systematic review and network meta-analysis, we compare the effects of drug prophylaxis for covid-19. This living network meta-analysis will, similar to our established living network meta-analysis on covid-19 treatment, directly inform living World Health Organization guidelines on drugs for covid-19, a collaborative effort between WHO and the MAGIC Evidence Ecosystem Foundation (www.magicproject.org), inspired by BMJ Rapid Recommendations. This review will inform trustworthy, actionable, and living guidance to clinicians caring for patients with covid-19 (also see box 1).

Methods
The protocol provides detailed methods of this systematic review (see supplementary file). We report this living systematic review following the guidelines of the preferred reporting items for systematic reviews and network meta-analyses (PRISMA) checklist. A living systematic review is a cumulative synthesis that is updated regularly as new evidence becomes available. The linked BMJ Rapid Recommendations methods team approved all decisions relevant to data synthesis.

Eligibility criteria
We included randomised trials in participants at risk of covid-19 and that compared different drugs or therapeutic doses of vitamins or antibodies for prophylaxis against each other or against no prophylaxis (placebo or standard care, as defined by the researchers), with no restriction on language of publication. We included studies of people pre-exposure or post-exposure to covid-19 and at low risk for covid-19 (eg, non-exposed community member) or high risk (eg, member of a household where one or more people tested positive for SARS-CoV-2, contact of index case, healthcare worker, or long term care resident).

Randomised trials were excluded if they were published only as press releases or evaluated vaccination, nutrition, or non-drug supportive care interventions. We synthesise randomised trials that evaluated drug, antibody, and cellular treatments in people with covid-19 in separate living network meta-analyses.

Information sources
From Monday to Friday we performed daily searches for eligible studies in the WHO covid-19 database—a comprehensive multilingual source of global literature on covid-19. We also performed daily searches (Monday to Friday) in the US Centers for Disease Control and Prevention (CDC) COVID-19 Research Articles Downloadable Database before its merger with the WHO covid-19 database on 9 October 2020. The WHO database includes, but is not limited to, 25 bibliographic and grey literature sources: Medline (Ovid and PubMed), PubMed Central, Embase, CINAHL, ProQuest Central, SciFinder, Scopus, Academic Search Complete, Africa Wide Information, CINAHL, ProQuest Central, SciFinder, the Virtual Health Library, LitCovid, WHO covid-19 website, CDC covid-19 website, Eurosurveillance, China CDC Weekly, Homeland Security Digital Library, ClinicalTrials.gov, bioRxiv (preprints), medRxiv (preprints), chemRxiv (preprints), and SSRN (preprints). The supplementary file includes the WHO literature search strategy, which is maintained and tested on an ongoing basis by two WHO research librarians and one US CDC research librarian.

We designed the daily searches to match the update schedule of the database and to capture eligible studies the day of or the day after publication. To identify randomised trials, we filtered the results through RobotSearch, a validated and highly sensitive machine learning model. We tracked preprints of randomised...
Box 1: Linked resources in this BMJ Rapid Recommendations cluster

- Lamontagne F, Agoritsas T, Siemieniuk R, et al. A living WHO guideline on drugs to prevent covid-19. BMJ 2021;372:n526, doi:10.1136/bmj.n526
- World Health Organization. Drugs to prevent COVID-19: A WHO living guideline. 2021. https://apps.who.int/iris/bitstream/handle/10665/339877/WHO-2019-nCoV-prophylaxes-2021.1-eng.pdf
  - Summary of the results from the Rapid Recommendation process
- Bartoszko JJ, Siemieniuk RAC, Kmu E, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ 2021;373:n949, doi:10.1136/bmj.n949
  - Review and network meta-analysis of all available randomised trials that assessed drug prophylaxis for covid-19
- MAGICapp (https://app.magicapp.org/#/guideline/L6RxYL)
  - Expanded version of the methods, processes, and results with multilayered recommendations, evidence summaries, and decision aids for use on all devices

trials until publication and, when discrepant, updated data to match those in the peer reviewed publication. When needed, we reconciled multiple versions of preprints, post hoc analyses, corrections, and retractions.

In addition, monthly searches, utilising search terms for covid-19 developed by the CDC and adapted for the Chinese language by native speakers, were performed in six Chinese databases: Wanfang Data, Chinese Biomedical Literature, China National Knowledge Infrastructure, VIP Chinese Science Journals Database, Chinese Medical Journal Net (preprints), and ChinaXiv (preprints). The Chinese literature search also included search terms for randomised trials. The supplementary file includes the Chinese literature search strategy.

Our search strategy also included monitoring, on an ongoing basis, living evidence retrieval services, including the Living Overview of the Evidence (LOVE) covid-19 Repository by the Epistemonikos Foundation and in collaboration with the Cochrane Canada Centre at McMaster University, the Systematic and Living Map on covid-19 Evidence by the Norwegian Institute of Public Health.15 16

The search included WHO information sources from 1 December 2019 to 25 March 2021, and the Chinese literature from conception of the databases to 20 February 2021.

Study selection and data collection
Using a systematic review software, Covidence,17 after training and calibration exercises, pairs of reviewers independently screened all titles and abstracts, followed by full texts of trials that were identified as potentially eligible. A third reviewer adjudicated conflicts.

For each eligible trial, after training and calibration exercises, pairs of reviewers extracted data independently using a standardised, pilot tested data extraction form. Reviewers collected information on trial characteristics (trial registration, publication status, study status, design), participant characteristics (country, age, sex, comorbidities), exposure characteristics (exposure status, exposure duration, high risk group), and outcomes of interest (means or medians and measures of variability for continuous outcomes, and number of participants analysed and number of participants who experienced an event for dichotomous outcomes). Reviewers resolved discrepancies by discussion and, when necessary, with adjudication by a third party.

The review team selected outcomes of interest based on importance to patients, and these were informed by clinical expertise in the systematic review team and the linked guideline panel responsible for the WHO living guideline on drugs to prevent covid-19.6 The panel, detailed in the guideline, includes unconflicted clinical experts and patient partners who were recruited to ensure global representation. We rated outcomes from 1 to 9 based on importance to individual patients (9 being most important), and we included any outcome rated 7 or higher by any panel member. This process resulted in choice of several outcomes: laboratory confirmed SARS-CoV-2 infection; a composite of suspected, probable, or laboratory confirmed SARS-CoV-2 infection; admission to hospital (within 28 days of randomisation); mortality (closest to 90 days); adverse effects leading to drug discontinuation (within 28 days of randomisation); and time to symptom resolution or clinical improvement in the subset of participants who became infected with SARS-CoV-2.

In anticipation of hydroxychloroquine prophylaxis being included in the linked WHO recommendation, we analysed drug specific adverse effects from trials reporting on hydroxychloroquine compared with standard care or placebo. The supplementary file includes the results of pairwise meta-analyses and related subgroup analyses for cardiac toxicity and nonserious gastrointestinal adverse effects.

Because of inconsistent reporting across trials, when possible we preferentially extracted participant characteristics and outcome data for participants with a negative polymerase chain reaction (PCR) test result for SARS-CoV-2 infection at baseline. If authors did not report data separately for those who were PCR negative for SARS-CoV-2 at baseline, we extracted data from all participants, regardless of their PCR status at baseline.

Risk of bias within individual studies
For each eligible trial, after training and calibration exercises, reviewers used a revised version of the Cochrane tool for assessing risk of bias in randomised trials (RoB 2.0)18 to rate trials at the outcome level as either: low risk of bias; some concerns—probably low risk of bias; some concerns—probably high risk of bias; or high risk of bias, across the following domains: bias arising from the randomisation process; bias due to departures from the intended intervention; bias due to missing outcome data; bias in measurement of the outcome; bias in selection of the reported results, including deviations from the registered protocol; bias arising from early termination owing to benefit; and bias arising from competing risks. We rated trials at high risk of bias overall if one or more domains were rated as some concerns—probably high risk of bias, or as high risk of bias and as low risk of bias overall if
all domains were rated as some concerns—probably low risk of bias or low risk of bias. Reviewers resolved discrepancies by discussion and, when not possible, with adjudication by a third party.

Data synthesis

Summary measures

The effect of interventions on dichotomous outcomes were summarised using odds ratios and corresponding 95% credible intervals. To mitigate results with highly implausible and extremely imprecise effect estimates, the analyses included only prophylactic drugs associated with at least 100 participants or 20 events, regardless of the number of studies in which the drug was assessed or the number of participants who received the drug in each study. The analysis plan included, data permitting, adjustment for cluster randomisation.

Treatment nodes

We created nodes for each prophylactic drug (or combination of drugs), independent of dose or duration. Standard care and placebo arms across included trials were combined into a single node for analyses. The networkplot command of Stata version 15.1 (StataCorp, College Station, TX) provided software for network plots in which the inverse variance of the direct comparison determined the thickness of lines between nodes and the size of nodes.

Statistical analysis

For outcomes with sufficient data (ie, laboratory confirmed SARS-CoV-2 infection, and suspected, probable, or laboratory confirmed SARS-CoV-2 infection), we performed random effects network-meta analysis using the R package geMTC20 and used three Markov chains with 100 000 iterations after an initial burn-in of 10 000 and a thinning of 10. Node splitting models provided methods to obtain indirect estimates and to assess local heterogeneity.21 For all other outcomes, we performed random effects bayesian meta-analysis using bayesmeta package in RStudio version 3.5.3 (R Studio, Boston, MA).22 An empirical study provided the basis for choosing a plausible prior for the variance parameter and a uniform prior for the effect parameter.23 Outcomes were analysed regardless of whether they were prespecified in a protocol or trial registration. The foundational R codes are publicly available at https://github.com/covid19lnma/prophylaxis_NMA.

Certainty of the evidence

The grading of recommendations assessment, development, and evaluation (GRADE) approach for network meta-analysis provided the framework for assessing the certainty of evidence.7 26 Two methodologists with experience in using GRADE rated each domain for each comparison and outcome separately and resolved discrepancies by discussion. Criteria for rating the certainty for each comparison and outcome as high, moderate, low, or very low, included considerations of risk of bias, inconsistency, indirectness, publication bias, imprecision (eg, from lack of power as a result of very low event rates). When the credible interval suggested an effect, we used optimal information size to inform the GRADE rating for imprecision.24 Judgments of imprecision for this systematic review were made using a minimally contextualised approach.25 This approach considers whether credible intervals include the null effect, or, when the point estimate is close to the null effect, whether the credible interval lies within the boundaries of small but important benefit and harm.

We rated the certainty of no important effect for the outcomes laboratory confirmed infection; suspected, probable, or laboratory confirmed infection; admission to hospital; and mortality. Pending data from quantitative studies of patient values, we chose thresholds of small but important effects of 0.5% for mortality, 3% for infection (whether laboratory confirmed or not), and 1% for admission to hospital. We rated the certainty of an increase or decrease in adverse effects leading to discontinuation of a drug using the null effect as a threshold. GRADE evidence summaries (Summary of Findings tables) in the MAGIC Authoring and Publication Platform (www.magicapp.org) provided user friendly formats for clinicians and patients and allowed reuse in the context of clinical practice guidelines for covid-19, such as the WHO living guidelines.5 6 Interim updates and additional study data will appear on our website (www.covid19lnma.com).

Interpretation of results

To facilitate interpretation of the results, we calculated absolute effects for outcomes in which the summary measure was an odds ratio. For mortality, we used the event rate among all participants randomised to standard care or placebo to calculate the baseline risk. For all other outcomes, we used the median event rate in the standard care or placebo arms to calculate the baseline risk. We categorised the interventions from the most to the least effective using the minimally contextualised GRADE guidance to drawing conclusions from network meta-analyses, which considers the effect estimates and the certainty of the evidence.25

Subgroup and sensitivity analysis

The analysis plan included performing subgroup analyses of pre-exposure versus post-exposure studies, preprints versus peer reviewed studies, and high versus low risk of bias studies when at least two studies were present for each subgroup. We plan on performing network meta-regression to explore if duration of prophylactic drug use might modify the relative effect of the drug on adverse effects leading to discontinuation, hypothesising that if the drug is active at the time of exposure to covid-19, it will have a greater relative effect. The linked independent WHO
of the outcomes of interest. Two trials were initially posted as preprints and subsequently published in peer reviewed journals and three texts.

Of the 11 eligible randomised trials, seven were published in peer reviewed journals and three only as preprints, and one was a clinical trial registry that reported results. All trials were registered, published in English, and compared prophylactic drugs with standard care or placebo.

Six evaluated prophylactic drugs in participants without documented exposure to Covid-19 (pre-exposure) and four evaluated prophylactic drugs in participants with documented exposure to Covid-19 (post-exposure). One trial evaluated prophylactic ivermectin in participants both pre-exposure and post-exposure to Covid-19. Five trials—four evaluating hydroxychloroquine and one evaluating bromhexine hydrochloride—reported on adherence to drug prophylaxis. Full adherence to drug prophylaxis ranged from 75% to 95%. Table 1 presents the characteristics of the 11 included studies, including prophylactic drug dose and duration of use and extent and setting of participant exposure to Covid-19.

Seven trials reported results for one or more outcomes of interest that were not prespecified in protocols or registrations. The protocols and trial reports included no other discrepancies in reporting of the outcomes of interest. Two trials were initially posted as preprints and subsequently published in full after peer review.

Another trial published results on a trial registry and subsequently published as a peer reviewed publication. Of the trials with multiple published versions, three showed discrepancies in patient baseline characteristics. Two trials showed discrepancies in outcome reporting. Four trials had discrepancies that affected risk of bias ratings. The supplementary file presents additional study characteristics, outcome data, and reporting differences between versions of study preprints, peer reviewed publications, or both.

Analyses were performed on 1 August 2022 by guest. Protected by copyright.
Laboratory confirmed SARS-CoV-2 infection

Eight trials that reported on laboratory confirmed SARS-CoV-2 infection in 5728 participants with a negative PCR test result at baseline were included in random effects bayesian network meta-analysis. The network nodes comprised hydroxychloroquine, ivermectin combined with iota-carrageenan, ivermectin alone, and standard care or placebo. Hydroxychloroquine, compared with standard care or placebo, probably does not reduce the risk of laboratory confirmed infection (odds ratio 1.03 (95% credible interval 0.71 to 1.47); risk difference 2 more

Hydroxychloroquine has trivial to no effect on mortality results are presented from pairwise meta-analyses. In random effects bayesian network meta-analysis consisting of nodes for hydroxychloroquine, ivermectin, and standard care or placebo. For the outcome hospital admission, moderate certainty of evidence suggests that hydroxychloroquine, compared with standard care or placebo, may have trivial to no effect (0.90 (0.58 to 1.31); 15 fewer per 1000 participants (64 fewer to 41 more); the certainty of evidence was rated down because of serious risk of bias and imprecision. Owing to very low certainty of evidence, the effect of ivermectin, compared with standard care, in reducing the risk of suspected, probable, or laboratory confirmed infection remains very uncertain (0.06 (0.02 to 0.13); 159 fewer per 1000 participants (165 fewer to 144 fewer); the certainty of evidence was rated down because of serious risk of bias and very serious imprecision.

Adverse effects leading to drug discontinuation
Four trials reported adverse effects leading to drug discontinuation in 3616 participants randomised to hydroxychloroquine, standard care, or placebo. For trials on other prophylactic drugs eligible for analysis did not report any adverse effects leading to drug discontinuation, precluding network meta-analysis. Hydroxychloroquine probably increases adverse effects compared with standard care or placebo (2.34 (0.93 to 6.08); 19 more per 1000 participants (1 fewer to 70 more); moderate certainty of evidence because of imprecision; fig 2).

Time to symptom resolution or clinical improvement
No randomised trials reported on time to symptom resolution or clinical improvement in the subset of participants who developed SARS-CoV-2 infection.

Subgroup analysis
Insufficient data precluded subgroup analysis for trials randomising participants to ivermectin alone or to ivermectin combined with iota-carrageenan versus standard care. Thus, subgroup analysis in the current study was limited to hydroxychloroquine trials only. No statistical evidence was found of differences in laboratory confirmed SARS-CoV-2 infection; suspected, probable, or laboratory confirmed SARS-CoV-2 infection; hospital admission, or adverse effects leading to discontinuation between pre-exposure and post-exposure studies or based on hydroxychloroquine dosing regimens (see supplementary file). Extremely low event rates precluded investigation of subgroup effects for mortality.

Discussion
This living systematic review and network meta-analysis provides a comprehensive overview of the evidence for prophylaxis against covid-19 up to 25 March 2021 and directly informs WHO living guidelines on prophylaxis. The comparisons for which evidence was informative were hydroxychloroquine versus no prophylaxis, ivermectin combined with iota-carrageenan versus no prophylaxis, and ivermectin versus no prophylaxis. Of these comparisons, it is highly uncertain whether ivermectin combined with iota-carrageenan and ivermectin alone reduces the risk of patient important outcomes.
| Study, country | Publication status (registration) | No of participants | Mean age (years) | % male | Comorbidities | Participant type and exposure characteristics | Type of prophylaxis | Treatments (dose and duration) | Outcomes |
|----------------|-----------------------------------|--------------------|-----------------|--------|---------------|---------------------------------------------|---------------------|-------------------------------|----------|
| Abella 2020,30 (PATCH), USA | Published (NCT0329923) | 132 | 30.0 | 31.1 | Cardiac disease (0%), diabetes (0.4%), hypertension (1.9%), asthma (17.4%), chronic obstructive pulmonary disease (6.0%) | Healthcare workers who work ≥20 hours weekly in hospital based units | Pre-exposure (98.5%) | Hydroxychloroquine (600 mg once daily for 8 weeks), placebo | Mortality, infection with covid-19 (laboratory confirmed), admission to hospital, adverse events leading to drug discontinuation |
| Amat-Santos 2020* (RASTAVI), Spain | Published (NCT01201185) | 102 | 83.3 | 56.9 | Aortic stenosis (100%), previous atrial fibrillation (27.5%), coronary artery disease (25.5%), peripheral vascular disease (10.8%), previous percutaneous coronary intervention (19.6%), previous myocardial infarction (5.9%), previous stroke or transient ischaemic attack (54.4%), diabetes (20.6%), hypertension (53.9%), chronic obstructive pulmonary disease (5.9%) | Patients with aortic stenosis successfully treated with transcatheter aortic valve replacement | Pre-exposure (100%) | Rampiril (10 mg once daily for 6 months), standard care | Mortality, infection with covid-19 (laboratory confirmed), admission to hospital |
| Barnabas 2020,34 USA | Published (NCT0328961) | 829 | 39.0 | 40.2 | NR | Individuals who had close contact with a person with confirmed covid-19 within 96 hours, in a healthcare (17.7%) or household (82.3%) setting | Post-exposure (100%) | Hydroxychloroquine (400 mg once daily for 3 days, then 200 mg once daily for 11 days), placebo | Infection with covid-19 (laboratory confirmed), admission to hospital |
| Bouwmeester 2020,28 USA and Canada | Published (NCT04308668) | 821 | 40.0 | 48.4 | Cardiovascular disease (0.7%), diabetes (1.4%), hypertension (12.1%), asthma (2.7%), chronic lung disease (0.4%) | Individuals exposed to a person with confirmed covid-19 at a distance of <6 ft (1.8 m) for >10 minutes, wearing no personal protective equipment or just a face mask, in a healthcare (66.4%), household (29.8%), or occupational setting (3.3%) | Post-exposure (100%) | Hydroxychloroquine (800 mg once, followed by the same dose one week later), placebo | Mortality, infection with covid-19 (laboratory confirmed and suspected), admission to hospital, adverse events leading to drug discontinuation |
| Chahla 2021,35 (Ivercar-Tuc), Argentina | Clinical trial registry reporting results NCT04701710 | 234 | 39.0 | 46.2 | Not reported | Healthcare workers who perform patient care and administrative tasks | Pre-exposure (100%) | Ivermectin (400 µg/kg once, followed by the same dose one week later), standard care | Infection with covid-19 (laboratory confirmed) |
| Elgazzar 2021* (Ivercav), Egypt | Preprint (NCT04668469) | 200 | 57.2 | 73.5 | Ischaemic heart disease (2.0%), diabetes (17.0%), hypertension (14.5%), bronchial asthma (4.5%) | Healthcare or household patients’ contacts, or both | Pre-exposure (not reported), post-exposure (not reported) | Ivermectin (400 µg/kg once, followed by the same dose one week later), standard care | Infection with covid-19 (laboratory confirmed) |
| Grau-Pujol 2020,31 Spain | Preprint (NCT04331834) | 269 | 39.9 | 26.8 | Diabetes (0.4%), hypertension (1.9%), chronic respiratory conditions (2.6%) | Healthcare workers working at least 3 days a week in a trial hospital | Pre-exposure (100%) | Hydroxychloroquine (400 mg once daily for 4 days, then 400 mg once weekly for 6 months), placebo | Infection with covid-19 (laboratory confirmed), adverse events leading to drug discontinuation |
| Mikhaylov 2021*,37 Russia | Preprint (NCT04405999) | 50 | 40.6 | 42.0 | Hypertension (6.0%) | Healthcare workers employed in emergency departments that admit patients with confirmed or suspected covid-19 | Pre-exposure (100%) | Bromhexine hydrochloride (8 mg three times daily), standard care | Mortality, infection with covid-19 (laboratory confirmed), infection with covid-19 (laboratory confirmed and suspected), admission to hospital, adverse events leading to drug discontinuation |
| Mitja 2020,27 (BCN PEP-COV), Spain | Published (NCT04304053) | 2525 | 48.7 | 27.1 | Cardiovascular disease (13.3%), cardiac arrhythmia (0%), respiratory condition (4.8%) | Individuals exposed to a person with confirmed covid-19 at a distance of <6 ft (1.8 m) for >15 minutes in a healthcare (60.3%), household (27.7%), or long term care setting (12.2%) | Post-exposure (100%) | Hydroxychloroquine (800 mg on day 1, then 400 mg once daily for 6 days), standard care | Mortality, infection with covid-19 (laboratory confirmed), infection with covid-19 (laboratory confirmed and suspected), admission to hospital, adverse events leading to drug discontinuation |
| Rajasingham 2020,29 (COVID PREP), USA and Canada | Published (NCT0328467) | 1483 | 41.0 | 48.8 | Cardiovascular disease (0.7%), diabetes (3.4%), hypertension (13.8%), asthma (10.1%) | Individuals who had exposure to a person with confirmed covid-19 in a healthcare setting (100%) | Pre-exposure (100%) | Hydroxychloroquine (400 mg once daily for 12 weeks), placebo | Mortality, infection with covid-19 (laboratory confirmed), infection with covid-19 (laboratory confirmed and suspected), admission to hospital |
| Shouman 2021,38 Egypt | Published (NCT04422561) | 340 | 38.7 | 51.3 | Cardiomyopathy (0.7%), ischaemic heart disease (2.3%), diabetes (7.6%), hypertension (9.5%), bronchial asthma (3.0%) | Individuals who had exposure to a family contact with confirmed covid-19 | Post-exposure (100%) | Ivermectin (15-24 mg once daily depending on weight, for 2 days), standard care | Mortality, infection with covid-19 (laboratory confirmed and suspected) |

*Not included in the network meta-analysis.
These findings are consistent with those reported in a meta-analysis of hydroxychloroquine prophylaxis compared with no prophylaxis, which did not find any statistical evidence of a benefit with hydroxychloroquine prophylaxis for the patient important outcomes of SARS-CoV-2 infection, hospital admission, and mortality. The study concluded that hydroxychloroquine is likely to increase the risk of adverse effects. Furthermore, the data are consistent with three meta-analyses and one network meta-analysis evaluating ivermectin as treatment for covid-19. In contrast with other meta-analyses, we rated the certainty as very low because of serious risk of bias and very serious imprecision.

The risk of death is much lower in people at risk of covid-19 than in those with a diagnosis of covid-19. Similarly, the risk of SARS-CoV-2 infection varies depending on pre-exposure or post-exposure status and setting. Research on prophylaxis therefore necessitates large trials or a focus on the highest risk populations to detect a possible benefit on outcomes of most importance to patients. Also, rare but important harms might not be detected by randomised trials unless extremely large numbers of participants are enrolled, they are diligently followed-up to ascertain these outcomes, or patients at greater risk are included. Guideline panels, which independently rate the certainty of the evidence, therefore must consider the trade-offs between concluding probably no benefit and meaningful adverse effects and waiting for more precise data. For example, the WHO living guidelines issued a strong recommendation against hydroxychloroquine for prophylaxis in covid-19.

**Strengths and limitations of this review**

This network meta-analysis on prophylaxis for covid-19 incorporates the most up-to-date evidence on hydroxychloroquine, ivermectin combined with iota-carrageenan, and ivermectin alone. It adds to our living systematic review on drugs for covid-19 and directly informs the WHO living guidelines, together constituting major innovations in the evidence ecosystem.

The search strategy was comprehensive, with explicit eligibility criteria and no restrictions on language of publication. To ensure expertise in all areas, our team includes clinical and methods experts who have undergone training and calibration exercises for all stages of the review process. To avoid spurious findings, we prespecified that we would only analyse interventions to which at least 100 people had been randomised or 20 events had been observed. Two trials—one of ramipril and one of bromhexine hydrochloride—were therefore omitted from the network meta-analysis, necessitated by the priority to avoid problems that arise from network meta-analysis of sparse data (uninformative and implausible results).

The GRADE approach provided the structure for rating certainty of evidence and interpreting the results considering absolute effects. To rate the GRADE domain of imprecision, we prespecified thresholds of effect that most would consider small but important. In the absence of empirical data, these thresholds represent our collective experience but are, to a large extent, arbitrary. People placing a larger or smaller value on certain outcomes might reasonably make different inferences about the certainty of evidence for no important effect. For example, people who consider that the smallest important effect in mortality is increasing or reducing 2 per 1000 or more deaths, would rate down the certainty of the evidence due to imprecision and conclude that hydroxychloroquine probably does not have an effect on this outcome (ie, moderate certainty evidence).

This review has some limitations. Conclusions for ivermectin are based on very low certainty evidence and we therefore anticipate that future studies evaluating

---

**Table: Summary of effects compared with standard care**

| Intervention                      | Laboratory confirmed SARS-CoV-2 infection | Suspected, probable, or laboratory confirmed SARS-CoV-2 infection | Admission to hospital | Mortality | Adverse effects leading to drug discontinuation | Time to symptom resolution or clinical improvement |
|-----------------------------------|------------------------------------------|---------------------------------------------------------------|-----------------------|-----------|-------------------------------------------------|---------------------------------------------------|
| Standard care*                    | 65 per 1000                              | 167 per 1000                                                  | 5 per 1000            | 3 per 1000| 15 per 1000                                     |                                                   |
| Hydroxychloroquine                | 2 (-18 to 28)†                           | -15 (-64 to 41)                                               | -1 (-3 to 4)          | -1 (-2 to 3)† | 19 (-1 to 70)                                  |                                                   |
| Ivermectin, iota-carrageenan      | -52 (-58 to -37)                         | -159 (-165 to -144)                                           | -1 (-3 to 68)†        |           |                                                 |                                                   |
| Ivermectin                        | -50 (-59 to -16)                         | -159 (-165 to -144)                                           | -1 (-3 to 68)†        |           |                                                 |                                                   |

Fig 2 | Summary of effects compared with standard care. *Row shows expected risk of each outcome with standard care. †Best estimate of effect obtained from direct evidence. Empty cells indicate that no evidence was available for the specific intervention. Numbers in coloured cells are estimated risk differences (95% credible intervals) per 1000 participants or mean differences (95% credible intervals) in days compared with standard care.
ivermectin for prophylaxis might substantially change the results, particularly for outcomes of infection and mortality.35 One cluster randomised trial did not report the design effect or the intrachuster correlation coefficient itself necessary to calculate the design effect, precluding adjustment in analyses, and therefore potentially leading to falsely narrow credible intervals.29 Cluster sizes were, however, small, making substantial bias unlikely.

The living nature of our systematic review and network meta-analysis could amplify publication bias because studies with promising results are more likely to be published and are published sooner than studies with negative results. Given the failure of hydroxychloroquine trials to show benefit, this is not a concern for hydroxychloroquine. This is, however, a concern for the evidence to date on ivermectin, for which most of the data has not been peer reviewed. With the inclusion of this data in network meta-analysis from one preprint,33 and one clinical trial registry reporting results,34 we found evidence of large positive effects; however, bias from simple errors and reporting limitations might have been introduced. We include these data, regardless of publication status and risk of bias, because of the urgent need for information and because so many of the studies on covid-19 are published first as preprints.

Another limitation of the evidence to date is lack of blinding, which might introduce bias through differences in co-interventions between randomisation groups, especially when the outcomes clinically suspected and probable infection are measured, and adverse effects lead to discontinuation of the drug. We chose to consider the treatment arms that did not receive an active experimental drug (ie, placebo or standard care) within the same node; it is possible that unblinded standard care groups29 33 35-37 might have received systematically different co-interventions or changed their personal protective behaviours compared with groups randomised to a placebo.28 30-34 Laboratory confirmation mitigates risk of bias from lack of blinding in outcome measurement; however, the availability of diagnostic testing differs across health systems, warranting the additional use of a symptomatic case definition for infection. This was the case for most participants, including healthcare workers, enrolled in one study in the United States, which risked overestimating the incidence of infection in its use of a symptomatic definition for infection.28 44

We will periodically update this living systematic review and network meta-analysis. The changes from each version will be highlighted for readers, and the most updated version will be the one available in the publication platform. Previous versions will be archived in the supplementary material. This living systematic review and network meta-analysis will also be accompanied by an interactive infographic and a website for users to access the most updated results in a user friendly format (https://app.magicapp.org/public/guideline/L6RxYL, www.covid19lnma.com).

Conclusions
This living systematic review and network meta-analysis on prophylactic drugs for covid-19 provides evidence that hydroxychloroquine has trivial to no effect on mortality and hospital admission, probably increases the risk of adverse effects, and probably does not reduce the risk of laboratory confirmed SARS-CoV-2 infection. We are very uncertain if ivermectin with or without iota-carrageenan reduces the risk of SARS-CoV-2 infection and mortality owing to serious risk of bias and very serious imprecision, and the effect estimates are likely to change substantially with additional evidence from ongoing trials. No other drug has been studied in large enough trials to make any inferences about the effects of prophylaxis on covid-19.

AUTHOR AFFILIATIONS
1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
2Evidence Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, Gansu, China
3Department of Preventive Medicine, College of Medicine, Chosun University, Gwangju, Republic of Korea
4Department of Anesthesia, McMaster University, Hamilton, ON, Canada
5Department of Medicine, University of Toronto, Toronto, ON, Canada
6Division of General Internal Medicine & Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland
7Department of Medicine, McMaster University, Hamilton, ON, Canada
8Department of Medicine, Western University, London, ON, Canada
9Servicio de Clínica Médica del Hospital Alemán, Buenos Aires, Argentina
10Wolfson Palliative Care Research Centre, Hull York Medical School, York, UK
11Department of Medicine and Centre de recherche du CHU de Sherbrooke, Sherbrooke, QC, Canada
12Schwartz/Reisman Emergency Medicine Institute, Sinai Health, Toronto, ON, Canada
13Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada
14Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
15Department of Medicine, University of Kansas Medical Center, Kansas City, MO, USA
16Iberoamerican Cochrane Centre, Sant Pau Biomedical Research Institute (IB Sant Pau), Barcelona, Spain
17CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
18Epistemikos Foundation, Santiago, Chile
19C Evidence Center, Cochrane Chile Associated Center, Pontificia Universidad Católica de Chile, Santiago, Chile
20School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
21Institute of Health and Society, University of Oslo, Oslo, Norway
22Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, Netherlands
23Faculty of Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
24Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador
25DIEC is an emerging clinician-scientist research fellow, supported by the Canadian Allergy, Asthma and Immunology Foundation, the Canadian Society of Allergy and Clinical Immunology, and AllerGen NCE (the Allergy, Genes and Environment Network, funded through the Canadian Institutes of Health Research).

doi: 10.1136/bmj.n949 | BMJ 2021;373:n949 | the bmj
Contributors: RACS, JJB, LG, AQ, FK, and DZ contributed equally to the systematic review and are joint first authors. RACS, JJB, DZ, LG, EQ, and RB-P were the core team leading the systematic review. JJB, RC, RWMV, SM, YW, ZS, LY, MG, and AV-G identified and selected the studies. DZ, EQ, RWMV, AA, YW, KH, HP-H, MAH, SLM, AQ, and LY collected the data. AQ, LG, AK, DS, GHG, and LT analysed the data. RB-P, HPH, A, RWMV, and DC assessed the certainty of the evidence. SLM, FL, BR, TA, POV, GHG, MM, JDN, ML, BT, and GR provided advice at different stages. JJB, RACS, RB-P, and GHG drafted the manuscript. All authors approved the final version of the manuscript. RACS is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: This study was supported by the Canadian Institutes of Health Research (grant OHR-IRSC-0579001321; grant MM1-174897).

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coiDisclosure.pdf and declare: BS receives funding from PIPRA AG (www.pipra.ch) to conduct a systematic review and individual patient data meta-analysis on predictors of postoperative delirium in elderly people in 2020-21; funding from Mitacs Canada, Accelerate internship in partnership with Nestlé Canada to support his graduate student stipend from 2016 to 2018. Mitacs is a national, not-for-profit organisation that has designed and delivered research and training programmes in Canada, working with universities, companies, and both federal and provincial governments, and funding from the International Life Sciences Institute (ILSI) to support his graduate work for his 2015 academic year. In 2016-17, BS worked part-time for the Cornerstone Research Group (CRG), a contract research organisation. The ILSI funding and being employed by CRG are outside the required three year period requested on the ICMJE form. ML reports personal fees and non-financial support from Sanofi, grants and personal fees from Seqirus, and personal fees from Pfizer and Medicago outside the submitted work; and is co-investigator on an Anti-Coronavirus Therapies (ACT) randomised trial of covid-19 treatment. LG reports grants from the Ministry of Science and Technology of China, outside the submitted work. All other authors report no financial relationships with any organisations that might have an interest in the submitted work in the previous three years and no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Not required.

Data sharing: No additional data available.

The manuscript’s guarantor (RACS) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported, that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Dissemination to participants and related patient and public communities: The infographic and MAGICapp decision aids (available online) explained. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Provenance and peer review: Not commissioned; externally peer reviewed.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non-Commercial (CC-BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

1 Johns Hopkins University. Coronavirus Resource Center. 2020 https://coronavirus.jhu.edu/map.html accessed April 27 2020.

2 Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions. Updated March 24 2021. www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-sampling/variant-info.html.

3 Krakower DS, Jain S, Mayer KH. Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis. Curr HIV/AIDS Rep 2015;12:127-38. doi:10.1007/s11904-014-0253-5

4 Vandvik PO,brigandello-petersen R, Guyatt GH. Living cumulative network meta-analysis to reduce waste in research: A paradigmatic shift for systematic review?BMJ: 2016;14:59. doi:10.1186/s12916-016-0596-4

5 Rochweg B, Siemieniuk RA, Agoritsas T, et al. A living WHO guideline on drugs for covid-19. BMJ 2020;370:m3379.

6 Lamogange F, Agoritsas T, Siemieniuk R, et al. A living WHO guideline on drugs to prevent COVID-19. BMJ 2021;372:n526.

7 Puhan MA, Schunemann HJ, Murad MH, et al, GRADE Working Group. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630.

8 Siemieniuk RAC, Bartoszko JI, Le L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 2020;370:m2980.

9 Siemieniuk RA, Agoritsas T, Macdonald H, Guyatt GH, Brandt L, Vandvik PO. Introduction to BMJ Rapid Recommendations. BMJ 2016;354:i5191.

10 Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84.

11 Elliott JH, Synnot A, Turner T, et al. Living Systematic Review Network. Living systematic review: 1. Introduction—the why, what, when, and how. J Clin Epidemiol 2017;91:23-30.

12 World Health Organization. Global research on coronavirus disease (COVID-19). www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-n cov

13 The Stephen B. Thacker CDC Library. COVID-19 Articles Downloadable Database: U.S. Centers for Disease Control and Prevention (CDC). 2020 www.cdc.gov/library/researchguides/2020/novelcoronavirus/researcharticles.html [accessed 6 May 2020].

14 Marshall J, Noël-Storr A, Kuiper J, et al. Machine learning for identifying Randomized Controlled Trials: An evaluation and practitioner’s guide. Res Synth Methods 2020;11:602-14.

15 Living evidence Repository for COVID-19. Epistemonikos Foundation. https://appliedevidence.com/loves/?5ee5d9566308e4ac0727071d [Accessed 10 August 2020].

16 Norwegian Institute of Public Health. NIPH systematic and living map on COVID-19 2020. www.nornesk.no/forskningskart/NIPH_mainMap.html [accessed 6 May 2020].

17 Covidence systematic review software. Melbourne, Australia: Ventas Health Innovation.

18 Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366l4898.

19 Chanani A, Higgins JP, Mavridis D, Sp Adoption P, Salanti G. Graphical tools for assessing the risk of bias in randomised trials. Res Synth Methods 2018;9:602-14.

20 gentm: Network meta-analysis using Bayesian methods [program]. R package version 0.8-4, version, 2020.

21 van Valkengoed G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res Synth Methods 2016;7:80-93. doi:10.1002/ rsm.1161.

22 Roever C. Bayesian random-effects meta-analysis using the baymeta R package. J Stat Softw 2020;93:1-51. doi:10.18637/jss v093i06.

23 Turner RM, Jackson D, Wei Y, Thompson SG, Higgins JP. Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. Stat Med 2015;34:984-98. doi:10.1002/sim.6381.

24 Brigandello-Petersen R, Bonner A, Alexander PE, et al. GRADE Working Group. A GRADE approach to rate the certainty in estimates from a network meta-analyses. J Clin Epidemiol 2018;93:36-44.

25 Brigandello-Petersen R, Flores ID, Izovich A, et al. GRADE working group. GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ 2020;371:m3900. doi:10.1136/bmj.m3900.

26 Schandelmaier S, Briel M, Varadhan R, et al. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ 2020;192:E901-6. doi:10.1503/cmaj.200077.

27 Amat-Santos I, Santos-Martínez S, López-Otero D, et al. Ramipril in High-Risk Patients With COVID-19. J Am Coll Cardiol 2020;76:268-76. doi:10.1016/j.jacc.2020.05.040.

28 Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med 2021;383:517-25. doi:10.1056/NEJMoa2016468.

29 Mitjà O, Corbacho-Monné M, Ulbas M, et al. BCN-PEP-CoV2 Research Group. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. N Engl J Med 2021;384:417-27.

30 Abella BS, Jolovskiy EL, Beney BT, et al. Prevention and Treatment of COVID-19 With Hydroxychloroquine (PATCH) Investigators. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. JAMA Intern Med 2021;181:195-202.

31 Grau-Pujol B, Campbru D, Martí-Soler H, et al. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial. Research Square 2020. doi:10.21203/rs.3.rs-72132/v1.

BMJ first published as 10.1136/bmj.n949 on 26 August 2021. BMJ: first published on 1 August 2022 by guest. Protected by copyright.http://www.bmj.com/
32 Rajasingham R, Bangdiwala AS, Nicol MR, et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. Clin Infect Dis 2020; published online 17 October. doi:10.1093/cid/ciaa1571
33 Elgazzar AE, Abdelaziz Y, Shamaa A, et al. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic, 28 December 2020, PREPRINT (Version 3). Research Square 2020.
34 Barnabas RV, Brown ER, Bershteyn A, et al. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial. Ann Intern Med 2021;174:344-52.
35 Shouman WM, Hegazy AA, Nafae RM, et al. Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomised Clinical Trial. J Clin Diagnos Res 2021; doi:10.7860/JCDR/2020/46795.0000
36 ClinicalTrials.gov. Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Lota-carrageenan (Ivercar-Tuc) [accessed 20 January 2021]. www.clinicaltrials.gov/ct2/show/NCT04701710.
37 Mikhailov EN, Lyubimtseva TV, Yakhrashev AD, et al. Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study. medRxiv 2021:2021.03.03.21252355.
38 Lofgren SMM, Nicol MR, Bangdiwala AS, et al. Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19 medRxiv 2020:2020.07.16.20155531.
39 Lewis K, Chaudhuri D, Alishamsi F, et al. GUIDE Group. The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis. A systematic review and meta-analysis of randomized trials. PLoS One 2021;16:e0244778. doi:10.1371/journal.pone.0244778
40 Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add on treatment in COVID-19: A systematic review and meta-analysis. J Pharm Pharm Sci 2020;23:462-9. doi:10.18433/jpps31457
41 Castañeda-Sabogal A, Chambergo-Michilot D, Toro-Huamancharumo CJ, et al. Outcomes of ivermectin in the treatment of COVID-19: a systematic review and meta-analysis medRxiv 2021:2021.01.26.21250420.
42 Hill A, Abdulamir A, Ahmed S, et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection, 19 January 2021, PREPRINT (Version 1) available at Research Square.
43 The COVID-NMA initiative. A living mapping and living systematic review of Covid-19 trials. Accessed 20 January 2021. https://covid-nma.com/treatments_tested/
44 Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol 2011;64:407-15.

Supplementary material: additional information